Autoimmunity & Inflammation

NKG Immunodeficient Mouse Models: Ensuring Success in Immunotherapy Research

Q: How has the development of immunodeficient mice evolved over the years?

The journey began with the discovery of the Athymic Nude mouse in the 1960s, which lacked T-cells. While revolutionary, these mice retained functional B and NK cells, limiting the types of human tissues they could accept. The improvement continued with the NOD Scid model, which addressed B-cell deficiency but was hindered by "leakiness" (residual immune activity) and a short lifespan. The major breakthrough came with the development of highly immunodeficient models, such as Cyagen’s NKG mouse. By knocking out the Il2rg gene on a NOD Scid background, researchers successfully eliminated T, B, and NK cells, creating the most receptive host for human cell engraftment to date.

Q: What were the key technical improvements in the latest generation of immunodeficient mice?

Modern improvements focus on three core areas: Longevity: Unlike older Scid models, the new generation (like NKG ) does not suffer from thymic lymphomas, allowing for long-term studies exceeding 12 months. Stability: Elimination of "leakiness" ensures that the mice do not spontaneously develop functional murine T or B cells as they age. Support for Humanization: The latest models are engineered to express specific human cytokines (e.g., IL-15, GM-CSF) to better support the survival and differentiation of specialized human immune cell subsets.

Q: What support does Cyagen provide for the development of customized HIS models?

Cyagen offers a comprehensive platform ranging from our proprietary NKG host strains to fully validated HSC-Humanized and PBMC-Humanized models . Furthermore, we provide customized gene-editing services to create niche models that express specific human cytokines or MHC molecules, tailored to your specific drug target requirements.

Q: Are BALB/c mice considered immunodeficient models?

No, standard BALB/c mice are immunocompetent, meaning they have a complete and functional immune system, including T-cells, B-cells, and Natural Killer (NK) cells. However, confusion often arises because the BALB/c Nude mouse—a popular immunodeficient model—is derived from the BALB/c background. Here is the breakdown: BALB/c (Wild-type): An immunocompetent inbred strain. It is widely used in immunology, inflammation, and vaccine research because it naturally biases toward a Th2 immune response. BALB/c Nude (Foxn1 ): An immunodeficient variant. Due to a mutation in the Foxn1 gene, these mice lack a thymus and cannot produce mature T-cells. They are also hairless, which is their most defining physical characteristic.

Cyagen Technical Content Team | November 19, 2025

NKG Mice: The Premier Host for Human Cell Engraftment

Achieve high-fidelity results in CAR-T and PDX studies with Cyagen's NKG immunodeficient models.

Contents

01. In Vivo Precision: Why Immunodeficient Mouse Models Define R&D Succes 02. Introducing NKG Mice: A Validated Platform for CAR-T and PDX Models 03. Accelerating Immunotherapy: A Proven Partnership in Preclinical Research 04. Advance Your Pipeline: Custom Immunodeficient Models for Discovery

Your CAR-T construct has just cleared its latest in vitro assay, showing potent and specific cytotoxicity. The data is clean, the mechanism is elegant, and the potential is immense. But between this promising result and a breakthrough publication lies the most unpredictable chasm in preclinical research: the in vivo study.

Have you ever felt that hesitation? The moment you select an animal model, you’re not just choosing a tool; you’re making a high-stakes bet. You’re betting that it will faithfully host your human-derived cells, that it won’t confound your results with residual immunity, and that it will survive long enough to yield meaningful data. A poor choice here doesn’t just mean a failed experiment. It means months of lost time, squandered funding, and a brilliant therapeutic concept stalled by the limitations of its platform. How many incredible discoveries have been derailed not by flawed science, but by a flawed vessel?

In Vivo Precision: Why Immunodeficient Mouse Models Define R&D Succes

Now, imagine a different path. Imagine planning your next CAR-T, PDX (Patient-Derived Xenograft), or human hematopoietic stem cell (HSC) study with a sense of quiet confidence. Imagine the primary variable is your therapeutic agent, not the stability of your model.

In this reality, you move from in vitro success to in vivo validation in a seamless, accelerated workflow. Your engraftment rates are high and predictable, allowing for smaller cohorts and more statistically powerful results. Your model is so profoundly immunodeficient that concerns over graft rejection or unexpected immune reactions simply fade into the background. You can focus on what truly matters: gathering the clean, translatable data that will illuminate your drug's true potential and pave the way for clinical translation. This isn’t a far-off ideal. It’s the strategic advantage researchers gain when they build their studies on a foundation of precisely engineered and rigorously validated immunodeficient models.

Introducing NKG Mice: A Validated Platform for CAR-T and PDX Models

Achieving this level of experimental clarity hinges on selecting a model that doesn’t just lack an immune system but is purpose-built for the specific demands of modern immunotherapy. While traditional nude and NOD scid mice laid the groundwork, today’s advanced therapies require a more sophisticated and reliable host.

For researchers pushing the boundaries of oncology and immunology, Cyagen’s portfolio of immunodeficient models provides the stable, validated foundation needed for success. The cornerstone of this portfolio, the NKG mouse, was engineered specifically to overcome the limitations of its predecessors.

Engineered for Unprecedented Receptivity: NKG mice exhibit deficiency of mature T cells, B cells, and functional NK cells, reduced complement activity, and weak phagocytosis of human-derived cells by macrophages due to the deletion of the Il2rg gene from NOD-Scid genetic background mice.
Confidence in Engraftment: This superior design translates directly to world-class performance. In studies developing CAR-T therapies, our models have demonstrated a high successful engraftment rate, virtually eliminating the risk and cost of model failure.
A Versatile Platform for Advanced Research: The NKG’s extreme immunodeficiency makes it the ideal host for a wide range of applications, including:
- CAR-T Cell Therapy: Assess efficacy and safety with a model that won’t reject your engineered cells.
- Patient-Derived Xenografts (PDX): Engraft human tumor tissues with high success rates to create avatars for personalized medicine studies.
- Human Immune System Reconstitution: Study the complexities of human immunity by
Built for Long-Term Studies: The robust health and extended lifespan of the NKG mouse support the long-term engraftment necessary to evaluate both the efficacy and the durability of novel treatments.

Accelerating Immunotherapy: A Proven Partnership in Preclinical Research

In science, trust isn't claimed; it's earned through data, repeatability, and shared success. For nearly two decades, Cyagen has worked alongside researchers in leading academic institutions and biotech firms, not as a vendor, but as a collaborative partner dedicated to solving the most difficult preclinical challenges.

The reliability of our immunodeficient models isn't just an internal metric; it's a conclusion validated by the global research community. The success of this partnership is documented in peer-reviewed publications, where scientists have leveraged our platforms to generate the pivotal data driving their fields forward. They chose these models because they needed a platform they could trust—one that had been rigorously characterized for immune cell deficiency, body weight, survival curves, and baseline physiology.

This extensive track record represents more than just a catalog of successful models. It’s a repository of shared experience. When labs developing next-generation immunotherapies partner with us, they aren't just acquiring an animal model; they are gaining access to a platform that has helped countless others like them turn visionary science into validated results. From establishing complex PDX models that mirror human tumor heterogeneity to confirming the in vivo potency of novel CAR-T constructs, our models have provided the biological canvas for discovery.

Advance Your Pipeline: Custom Immunodeficient Models for Discovery

Your research is too vital to be compromised by uncertainty. The time, resources, and intellectual energy you invest deserve a platform that de-risks your in vivo studies and amplifies your chances of success. It’s time to move your immunotherapy project forward on a foundation of proven reliability.

Take the next logical step on your research journey.

Explore our comprehensive portfolio of immunodeficient models to review detailed specifications, validation data, and application notes.

Or, for a more tailored approach, schedule a complimentary consultation with a scientific strategist to discuss your specific project goals and identify the optimal model to accelerate your path to discovery.